血清CYFRA21-1和CEA对非小细胞肺癌预后评价价值的Meta分析

Prognosis evaluation value of serum CYFRA21-1 and CEA level in non-small cell lung cancer:Meta analysis

目的：研究血清细胞角蛋白19片段（CYFRA21-1）和癌胚抗原（CEA）对非小细胞肺癌（NSCLC）患者的临床预后意义。方法通过检索PubMed、Springer Link、超星读秀中有关研究血清CYFRA21-1和CEA对NSCLC患者预后影响的文献，采用RevMan5.1软件进行荟萃分析（Meta分析），合并值为风险比（HR）。结果共入选8篇文献，累计NSCLC患者1569例。所有高水平血清CYFRA21-1的NSCLC患者的总生存估计合并HR＝1.63[95%可信区间（95%CI）：1.43～1.85， P＜0.05]，所有高水平血清CEA的NSCLC患者的总生存估计合并HR＝1.45（95%CI：1.26～1.66， P＜0.05），差异均有统计学意义。结论血清CYFRA21-1和CEA可作为NSCLC患者的预后评价指标，高血清CYFRA21-1较高血清CEA对评价NSCLC患者的预后不良更有价值，联合检测将更可靠。

Objective To evaluate the clinical significance of serum cytokeratin 19 fragment （CYFRA21-1） and carcinoma embryonic antigen（CEA） prognosis in non-small cell lung cancer（NSCLC） patients.MethodsAll the data dealing with the significance of serum CYFRA21-1 and serum CEA prognosis of NSCLC was researched from PubMed, Springer Link and Du Xiu database.The outcome was measured using the hazard ratio（HR）. Data pooling was performed by RevMan 5.1.Results One thousand five hundred and sixty-nine patients from 8 studies were included in the meta analysis. Merger HR estimate of overall survival for NSCLC patients with high serum CYFRA21-1 level was 1.63 （95%CI： 1.43-1.85,P〈0.05）. Merger HR estimate of overall survival for NSCLC patients with high serum CEA level was 1.45 （95%CI： 1.26-1.66,P〈0.05）.ConclusionSerumCYFRA21-1 and CEA can be regarded as a prognostic indicator of evaluation of NSCLC, high serum CYFRA21-1 in evaluation of NSCLC with poor prognosis is more valuable than high serum CEA, jointing detection will be more reliable.